Literature DB >> 32694249

LH Supplementation in Ovarian Stimulation for IVF: The Individual, LH Deficient, Patient Perspective.

Shahar Kol1.   

Abstract

The availability of recombinant follicle-stimulating hormone (FSH) and luteinizing hormone (LH) opens an opportunity to individualize ovarian stimulation. While the need for FSH in ovarian stimulation is universal, a question remains whether exogenous LH is beneficial. Previous population-based research showed that added LH is indicated in elderly and in profoundly LH depressed patients. This commentary explores potential individual patient parameters that may hint that this specific individual may prospectively need supplemented LH, irrespective of her age or experience from previous cycles. Specifically, it is suggested that in an antagonist protocol, the degree of LH recovery 24 h post first GnRH antagonist injection can identify those patients who may benefit from added LH. In addition, rising LH during the first 5 days of stimulation may predispose patients to a sharp LH drop following the first GnRH antagonist dose, and the need for added LH.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  GnRH antagonist; Individualized approach; Luteinizing hormone recovery; Ovarian stimulation; Supplemented luteinizing hormone

Mesh:

Substances:

Year:  2020        PMID: 32694249     DOI: 10.1159/000509162

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  2 in total

Review 1.  Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.

Authors:  Noemi Di Segni; Andrea Busnelli; Matteo Secchi; Federico Cirillo; Paolo Emanuele Levi-Setti
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-01       Impact factor: 6.055

2.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.